Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 29, 2026Journal of Clinical Oncology

Evaluating the impact of treatment timing with recombinant human thrombopoietin for cancer treatment–induced thrombocytopenia: A retrospective cohort study.

View Full Paper
Ask AI
Bookmark
Share

Authors

XWXin WangNanchong Central HospitalJBJun BieNanchong Central HospitalMYMi YangNanchong Central Hospital

Discussion

Loading...

Member takes

Implication

Retrospective cohort study evaluates treatment timing effects on chemotherapy continuity in CTIT patients, suggesting early interventions are more beneficial.

Key Points

  • This study investigates the clinical benefits of different timing strategies for initiating rhTPO treatment in patients with cancer treatment-induced thrombocytopenia.
  • Single-center retrospective cohort study of 456 patients with CTIT receiving rhTPO therapy.
  • Patients divided into three groups based on platelet counts at rhTPO initiation: early intervention and salvage therapy.
  • Comparative analyses included metrics such as time to platelet recovery and chemotherapy continuity.
  • Group 1 achieved platelet threshold in a median of 7.0 days, significantly faster than groups 2 and salvage (both 11.0 days, P < 0.001).
  • Severe CTIT incidence was reduced to 12.6% in group 1 and 19.2% in group 2, compared to 56.0% in salvage therapy (both P < 0.001).
  • Chemotherapy continuity improved with group 1 showing a delay/discontinuation rate of 18.9%, lower than the 33.1% in group 2 and 46.4% in salvage (all P < 0.05).

Cite This Study

Wang et al. (2026) studied this question.

synapsesocial.com/papers/6a192d7efab5b468c4416539https://doi.org/10.1200/jco.2026.44.16_suppl.12127
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A prospective study of the early treatment of recombinant human thrombopoietin for chemoradiation-induced thrombocytopenia in cervical squamous cell carcinoma patients.2026
  2. 2Efficacy and safety of recombinant human thrombopoietin (rhTPO) for thrombocytopenia induced by combinatorial interventional, targeted, and immunotherapy in hepatocellular carcinoma (SYNERGY-TPOACT): A retrospective cohort study.2026
  3. 3Recombinant Human Thrombopoietin Reduces the Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia2026
  4. 4A real‐world observation on thrombopoietic agents for patients with cancer treatment–induced thrombocytopenia in China: A multicenter, cross‐sectional study2024 · 19 citations
  5. 5836: MULTICENTER RCT OF RECOMBINANT HUMAN THROMBOPOIETIN FOR ICU SEPSIS WITH SEVERE THROMBOCYTOPENIA2026